Revenue segments as reported by the company.

Life Sciences Solutions

Analytical Instruments

Specialty Diagnostics

Laboratory Products and Services

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Amortization of acquisition-related intangible assets

Research and development

Restructuring and other costs

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Thermo Fisher Scientific

Life Technologies was a biotech company founded in November 2008 through a US$6.7 billion merger of Invitrogen Corporation and Applied Biosystems Inc. The joint sales of the combined companies were about $3.5 billion; they had about 9,500 employees, and owned more than 3,600 licenses and patents.

Life Technologies

Thermo Fisher Scientific, Inc. engages in the provision of analytical instruments, equipment, reagents and consumables, software, and services for research, analysis, discovery, and diagnostics. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. The Life Sciences Solutions segment is composed of a portfolio of reagents, instruments, and consumables used in biological and medical research, discovery and production of new drugs and vaccines, as well as diagnosis of infection and disease. The Analytical Instruments segment offers instruments, consumables, software, and services that are used for a range of applications in the laboratory, on the production line, and in the field. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments, and associated products used to increase the speed and accuracy of diagnoses. The Laboratory Products and Services segment is involved in providing everything needed for the laboratory, including a combination of self-manufactured and sourced products for customers in research, academic, government, industrial, and healthcare settings. The company was founded on October 11, 1960 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Thermo Fisher excels in 2022, eyes growth amid challenges

Thermo Fisher Scientific delivered exceptional 2022 results with strong Q4 performance and robust full-year revenue. Growth strategy and segment strengths position the company well for continued success in 2023.
Challenges such as normalization of growth, margin influences, and market dynamics require strategic management. Opportunities in high-growth markets and next-gen technologies offer avenues for further expansion and value creation.
Maintaining a focus on innovation, sustainability, and operational efficiency will be key to navigating challenges and capitalizing on growth opportunities in 2023.
Overall, Thermo Fisher Scientific's solid financial performance, strategic focus, and market positioning set a positive trajectory for continued success and value creation in the coming year.

Thermo Fisher excels in Q1 despite COVID challenges, eyes growth

Thermo Fisher Scientific's Q1 2023 showcased resilience amid challenges, driven by innovation and strategic initiatives. While facing short-term headwinds, the company remains well-positioned for long-term growth through market opportunities and operational strengths.

Thermo Fisher faces market challenges, focuses on cost management and acquisitions

Thermo Fisher Scientific navigated a challenging macroeconomic environment in Q2 2023, with varied performance across end markets. The company is focused on managing costs, driving productivity, and pursuing strategic acquisitions to enhance capabilities. Despite challenges, Thermo Fisher remains committed to ESG priorities and market outperformance.

Thermo Fisher reports solid Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 performance was solid, with revenue growth and strategic acquisitions driving market position strengthening.
While facing challenges like revenue impact in Q4 and customer caution, the company remains optimistic about industry outlook and growth opportunities.
The company's focus on innovation, ESG priorities, and operational efficiency positions it well for future growth and success.
Management's insights into 2024 outlook indicate a balanced approach to growth through strategic investments and operational improvements.

Thermo Fisher posts solid earnings, eyes growth amid market challenges

Thermo Fisher Scientific delivered strong financial performance in Q4 2023 and full-year 2023, driven by innovation and customer focus.
While facing challenges in certain segments and markets, the company remains optimistic about growth opportunities and market outpacing.
Strategic acquisitions, focus on sustainability, and operational excellence position Thermo Fisher for continued success in 2024 and beyond.
Guidance for 2024 indicates a focus on organic growth, stable segment margins, and a commitment to long-term market outperformance.

Thermo Fisher reports strong Q1 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q1 2024 earnings call highlighted strong financial performance driven by a proven growth strategy and disciplined capital deployment. While facing challenges in certain end markets and regulatory uncertainties, the company remains optimistic about future growth opportunities. Key strengths include innovation, strategic partnerships, and a focus on corporate social responsibility.

Thermo Fisher excels in Q2, raises 2024 guidance amid market challenges

Thermo Fisher Scientific's Q2 performance reflects resilience and strategic focus amidst market challenges. The company's emphasis on innovation, operational efficiency, and customer relationships positions it well for sustained growth. With a positive outlook for 2024 and a commitment to long-term success, Thermo Fisher remains a strong player in the industry.

Thermo Fisher excels in Q3 earnings, eyes growth opportunities

Thermo Fisher Scientific's Q3 2024 earnings call showcased strong financial performance, strategic innovations, and growth opportunities.
While facing challenges in certain market segments, the company's focus on innovation, partnerships, and financial strength positions it well for future growth.
With raised EPS guidance and revenue expectations, Thermo Fisher is poised for continued success through market expansion and strategic initiatives.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Charter Communications

Microsoft

NVIDIA

QUALCOMM

A stable U.S. economy, a partial trade deal with China, possible solution of Brexit and easy monetary policy of the Fed are likely to sustain Wall Street's rally in 2020.

5 Corporate Giants That Popped in 2019 and Have Upside Left

Thermo Fisher (TMO) gains from solid overseas expansion and acquisitions.

Thermo Fisher (TMO) at a 52-Week High: What's Driving It?

A series of product launches with better precision medicine initiatives aids Thermo Fisher's (TMO) performance.

Thermo Fisher Rides on New Product Suite and Global Growth

Thermo Fisher (TMO) reported earnings 30 days ago. What's next for the stock?

Thermo Fisher (TMO) Up 4.1% Since Last Earnings Report: Can It Continue?

QIAGEN

Shares of the Dutch diagnostic test manufacturer Qiagen popped after it confirmed ongoing buyout discussions with Thermo Fisher Scientific and others.

Will Thermo Fisher Buy Qiagen?

Alexion Pharma

AMETEK

IQVIA Hlds

Lowe's

Given the bullishness and record-high market, we have screened for five S&P 500 stocks that are most loved by the brokerage firms.

5 Most-Loved S&P 500 Stocks on Wall Street

Thermo Fisher Scientific Inc. TMO, -0.35% announced Friday a new $2.5 billion stock repurchase program, with no expiration date.

Thermo Fisher sets new $2.5 billion stock buyback program

Allstate

Intel

SYNNEX

Target

Stocks with a strong history of dividend growth year over year form a healthy portfolio with a greater scope of capital appreciation.

5 Excellent Dividend Growth Stocks on Sale

Thermo Fisher has been successful for many years at acquiring and integrating related companies but seems to be reorienting to organic growth.

Thermo Fisher Scientific: Moving From Inorganic To Organic Growth

Illumina

Which stock wins in a match-up between these two gene-sequencing leaders?

Better Buy:  Illumina vs. Thermo Fisher Scientific

Edwards Lifesciences

These health-related businesses managed to surprise themselves.

3 Healthcare Stocks With Heightened Expectations

Thermo Fisher Scientific, Inc. (TMO) CEO Marc Casper on Q3 2019 Results - Earnings Call Transcript

We are encouraged that three out of Thermo Fisher's (TMO) four business segments have registered strong year-over-year revenue growth in Q3.

Thermo Fisher (TMO) Beats on Q3 Earnings, Lifts Guidance

Boston Scientific

Boston Scientific earnings and Thermo Fisher earnings beat views modestly Wednesday. Both medtech stocks rose.

Boston Scientific, Thermo Fisher Earnings Beat Views; Medtech Stocks Rise

Thermo Fisher (TMO) delivered earnings and revenue surprises of 2.08% and 1.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Thermo Fisher Scientific (TMO) Q3 Earnings and Revenues Top Estimates

Comcast

Procter & Gamble

These stocks have provided their shareholders with some strong capital appreciation so far in 2019, in addition to lots of dividend income.

3 Dividend Stocks That Have Soared This Year

Thermo Fisher (TMO) registers a solid international performance with strong growth in Europe and Asia-Pacific including China.

Thermo Fisher Gets a Boost from Buyouts and Global Expansion

Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.

Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit

Investors continue to be optimistic about Thermo Fisher's (TMO) performance.

Here's Why You Should Add Thermo Fisher to Your Portfolio

Allegiant Travel Company

Booz Allen Hamilton Hld

Cracker Barrel Old Country Store

Dividend-paying securities are a major source of consistent income for investors when returns from the equity market are at risk.

7 Dividend Growth Stocks to Buy for October

Agilent Technologies

Danaher

General Electric

Increased use of reagents in the field of research, bioscience and genetics is pushing the biotechnology reagents market higher.

4 Stocks to Focus on Global Biotechnology Reagents Market

Thermo Fisher (TMO) Down 4.3% Since Last Earnings Report: Can It Rebound?

Nanometrics

Taiwan Semiconductor Manufacturing

Nanotech stocks cover a broad range of industries as their underlying innovation impacts all corners of business and society.
The post 4 Nanotech Stocks to Watch for Explosive Innovation appeared first on InvestorPlace.

4 Nanotech Stocks to Watch for Explosive Innovation

CEO of Thermo Fisher Scientific Inc (30-Year Financial, Insider Trades) Marc N Casper (insider trades) sold 50,000 shares of TMO on 07/30/2019 at an average price of $284.83 a share.

Thermo Fisher Scientific Inc (TMO) CEO Marc N Casper Sold $14.2 million of Shares

GlaxoSmithKline

Johnson & Johnson

It looks like 2019's going to be much better than expected for these giants operating in different corners of the healthcare sector.

News for Thermo Fisher Scientific Stock (TMO)